Get started
Author

Hiroshi Sootome

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
2010 · Hiroshi Hirai, Hiroshi Sootome, et al. · Molecular Cancer Therapeutics · 949
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
2020 · Hiroshi Sootome, Hidenori Fujita, et al. · Cancer Research · 215
PDF
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma
2024 · L. Goyal, D. DiToro, et al. · Annals of Oncology · 51
PDF
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use
2023 · Satoru Ito, Sachie Otsuki, et al. · ACS Medicinal Chemistry Letters · 50
PDF
Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.
2013 · Hiroaki Ochiiwa, Hidenori Fujita, et al. · Molecular Cancer Therapeutics · 28
TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways
2021 · Akihiro Miura, Hiroshi Sootome, et al. · Investigational New Drugs · 21
Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo : Preclinical Studies as Guidance for Clinical Development and Trial Design
2020 · Hiroshi Sootome, Akihiro Miura, et al. · Molecular Cancer Therapeutics · 20
Validation of universal conditions for duplex quantitative reverse transcription polymerase chain reaction assays
2006 · Tsuyoshi Ishii, Hiroshi Sootome, et al. · Analytical Biochemistry · 16
Abstract A271: TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors .
2013 · Hiroshi Sootome, Yayoi Fujioka, et al. · Molecular Cancer Therapeutics · 11
Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor‐Insensitive Breast Cancer Cells
2025 · Hiromi Muraoka, Hiromi Kazuno, et al. · Cancer Science · 6
PDF
Practical evaluation of universal conditions for four-plex quantitative PCR
2007 · Tsuyoshi Ishii, Hiroshi Sootome, et al. · Analytical and Bioanalytical Chemistry · 6
Abstract 1117: Acquired resistance to ATP-competitive and irreversible FGFR inhibitors (FGFRi's): A library-based approach
2021 · Hiroshi Sootome, Suzuko Kato, et al. · Cancer Research · 5
A cell-based screening method for specifically detecting kinase activity
2007 · Mikiya Suda, Tsuyoshi Ishii, et al. · Analytical and Bioanalytical Chemistry · 5
A Selective Cellular Screening Assay for B-Raf and c-Raf Kinases
2007 · Tsuyoshi Ishii, Hiroshi Sootome, et al. · SLAS DISCOVERY · 3
PDF
A Robust, Target-Driven, Cell-Based Assay for Checkpoint Kinase 1 Inhibitors
2007 · Tsuyoshi Ishii, Hiroshi Sootome, et al. · SLAS DISCOVERY · 3
PDF
Pharmacological characteristics and clinical effectiveness of Futibatinib (Lytgobi® Tablets), a covalently-binding, irreversible FGFR1–4 inhibitor
2024 · Katsuya Takagaki, Ryota Okude, et al. · Folia Pharmacologica Japonica · 2
PDF
Abstract 659: Synergistic antitumor activity of futibatinib (TAS-120), a FGFR1-4 inhibitor, and PI3K pathway inhibitors
2020 · Akihiro Miura, Hiroshi Sootome, et al. · Cancer Research · 2
Abstract 564: Futibatinib (TAS-120) plus chemotherapy demonstrates a synergistic effect across various FGFR-deregulated cancer cell lines and xenograft models
2020 · Hiroshi Sootome, Akihiro Miura, et al. · Cancer Research · 2
398 TAS-119 a selective inhibitor of Aurora A kinase, potentiates taxane therapy in breast and lung cancer models
2014 · Y. Nakatsuru, A. Hashimoto, et al. · European Journal of Cancer · 2
Abstract A272: Intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality.
2013 · Yoko Nakatsuru, Hiroaki Ochiiwa, et al. · Molecular Cancer Therapeutics · 2
252 TAS-2104, a Highly Potent and Selective Aurora A Inhibitor, Enhanced Antitumor Activity of Taxanes in Vivo
2012 · K. Ishihara, N. Masuko, et al. · European Journal of Cancer · 2
Abstract 4437: Pimitespib (TAS-116), an HSP90 inhibitor, overcomes resistance to androgen receptor pathway inhibitors in prostate cancer by simultaneously targeting several key resistance mechanisms
2025 · Hiromi Muraoka, Kazuhisa Minamiguchi, et al. · Cancer Research · 1
MO13-2 Covalent FGFR inhibitor futibatinib exhibits sustained antitumor effects compared with ATP-competitive inhibitors
2023 · Hiromi Muraoka, Hiroshi Sootome, et al. · Annals of Oncology · 1
Data from Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
2023 · Hiroshi Sootome, Hidenori Fujita, et al. · 1
Covalent FGFR inhibitor futibatinib exhibits sustained antitumor effects compared with ATP-competitive inhibitors by being less prone to ontarget resistance
2022 · H. Sootome, H. Muraoka, et al. · European Journal of Cancer · 1
PDF
Works count: 57
Citation count: 1,410
H-index: 9
I10-index: 9
Year
Topic
Type